4 October 2018 - The Department of Health and Social Care has asked the NICE to produce guidance on using idelalisib in the NHS in England for the treatment of patients with refractory follicular lymphoma.

Idelalisib is not recommended, within its marketing authorisation, for treating follicular lymphoma that has not responded to 2 previous lines of treatment in adults.

Idelalisib has not been compared directly with current chemotherapy treatments. So, it is unclear whether it is better, and if so by how much, than what the NHS currently offers.

Read NICE Appraisal Consultation Document